Dendritic cell vaccination in acute myeloid leukemia
Authors:
- Yannick WillemenYWYannick Willemen
- Eva LionELEva Lion
- Evelien L. SmitsESEvelien L. Smits
- Zwi N. BernemanZBZwi N. Berneman
- 1 July 2012
- journal article
- review article
- Published by Elsevier in Cytotherapy
- Vol. 14 (6) , 647-656
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Vaccines as consolidation therapy for myeloid leukemiaExpert Review of Hematology, 2011
- Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cellsHaematologica, 2010
- Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccinationProceedings of the National Academy of Sciences, 2010
- Immunotherapy prospects for acute myeloid leukaemiaClinical and Experimental Immunology, 2010
- Harnessing human dendritic cell subsets for medicineImmunological Reviews, 2010
- Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory propertiesJournal of Translational Medicine, 2009
- Transcriptional and functional defects of dendritic cells derived from the MUTZ‐3 leukaemia lineImmunology, 2009
- High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrowBlood, 2009
- Dendritic cells fused with core binding factor‐beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytesBritish Journal of Haematology, 2004